Chirosynkem laboratories Pvt Ltd

we specialize in the design and synthesis of small molecules, hit to lead optimization, email: [email protected],

[Chirosynkem laboratories Pvt Ltd @chirosynkem]

Are you looking for Customized synthesis service of small molecules?
#MedChem #customsynthesis #synthesisofsmallmolecules #drugdiscovery #processdevelopment #FTE #chemistryservices #CDMO #API #Pharma #ADC #PROTACs

[Chirosynkem laboratories Pvt Ltd @chirosynkem]

@KRHornberger we can make it for you

[Thomä Lab @LabThoma]

Interested in how #molecularglues do the gluing but only have a few minutes to spare? ⏰ Have a look at a one-page digest of our recent manuscript, a new @NaturePortfolio format: https://t.co/cHE1tjEyCk

[Project ESTELLA @project_estella]

📢Good news from @kemijski! Our partners have published an article (with Project ESTELLA in the acknowledgements) about lignin and covalent adaptable networks in ACS Sustainable Chemistry & Engineering 📄.
👉Click on the link to read the complete article: https://t.co/qO58R01PCh

[Guillaume Laconde @Glaconde34]

PROTAC-mediated CDK degradation differentially impacts cancer cell cycles due to heterogeneity in kinase dependencies https://t.co/EHT6KNrJkj

[Chirosynkem laboratories Pvt Ltd @chirosynkem]

The first FDA-approved treatment for Demodex Blepharitis, a common eyelid disease caused by microscopic mites living in the eyelashes' hair follicles. #Lotilaner
For more information blog:
https://t.co/WWF73x6JSj

[ACS Publications Bio & Med Chem Content @ACSBioMed]

Optimizing the drug-like properties should be your design focus for antibody-drug conjugates (ADC). Research from @AbbVie in #JMedChem

Read the article here ➡ https://t.co/dlcQ5kOGcD

[まいしん @chemist58409939]

discovery of LUNA18 as an orally bioavailable cyclic peptide KRAS inhibitor(Chugai Pharmaceutical Co. Ltd.)
https://t.co/nBIrebIfte

[Chirosynkem laboratories Pvt Ltd @chirosynkem]

@BtDavide Very nice publication

[Chirosynkem laboratories Pvt Ltd @chirosynkem]

Psoriatic disease: recent advances in small molecules. #psoriasis #Deucravacitinib
For more information blog: https://t.co/ADSREW3dio

[Chirosynkem laboratories Pvt Ltd @chirosynkem]

Treatment of sickle cell disease (SCD): Osivelotor (GBT-601), a second-generation drug. #sicklecelldisease #Osivelotor #GBT601
My blog: https://t.co/02RfvqiFwb

[Chirosynkem laboratories Pvt Ltd @chirosynkem]

The Latest Advancements in Small Molecule Drugs for Insomnia.#insomnia #Daridorexant #Lemborexant
My Blog: https://t.co/eYfdFi3JJl

[Chirosynkem laboratories Pvt Ltd @chirosynkem]

This is my Blog: https://t.co/i865nGOVsc

[Chirosynkem laboratories Pvt Ltd @chirosynkem]

Are you looking for Customized synthesis service of small molecules?
#MedChem #customsynthesis #synthesisofsmallmolecules #drugdiscovery #processdevelopment #FTE #chemistryservices #CDMO #API #Pharma #ADC #PROTACs

[Chirosynkem laboratories Pvt Ltd @chirosynkem]

Endometriosis and Uterine Fibroids: Gynecological Diseases https://t.co/VFyJlDXvHQ

[Chirosynkem laboratories Pvt Ltd @chirosynkem]

The Most Significant Advancement in HIV Treatment : Cabotegravir https://t.co/i5QFE7CxKh

[Chirosynkem laboratories Pvt Ltd @chirosynkem]

Sotagliflozin drug approved in May 2023 to treat Diabetes https://t.co/zrcIypy6FM

[Protein-Degraders @ProtDegraders]

23 PROTACs and 10 Molecular glues in the clinic! Am I missing anything?
https://t.co/b9vvkpZpmN

[Chirosynkem laboratories Pvt Ltd @chirosynkem]

@HennieValkenier We can assist you in designing and synthesizing small molecules at affordable prices. Furthermore, we will provide all experimental details and intellectual property (IP) rights exclusively to the customer.

[Chirosynkem laboratories Pvt Ltd @chirosynkem]

@MilesCcc Inspiration to us

[Chirosynkem laboratories Pvt Ltd @chirosynkem]

New class of oral small molecule drug: Ritlecitinib.
Ritlecitinib is used for treating severe alopecia areata, which causes hair loss on the scalp and other parts of the body. Litfulo was approved by the FDA in June 2023.
https://t.co/oK5uoZpXsV

[Chirosynkem laboratories Pvt Ltd @chirosynkem]

CNS drug: Ozanimod: In 2020, the FDA authorised ozanimod for the treatment of relapse multiple sclerosis, which includes active secondary progressive multiple sclerosis , clinically isolated syndrome, and relapsing-remitting multiple sclerosis.  https://t.co/13cWmHgpD0